Faruqi & Faruqi Investigates Inovio Investor Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy INO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating concerns about the company's financial health.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers to help them understand their legal rights and options.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price, as investor confidence may wane due to legal risks, further impacting the company's market performance and financing capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.460
Low
3.00
Averages
7.33
High
13.00
Current: 1.460
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
INOVIO to Present at Key Scientific Conferences on DNA Medicines
- Conference Participation: INOVIO will present its research on gene transfer in hemophilia A mice at the American Society of Gene and Cell Therapy Annual Meeting on May 12, 2026, showcasing the correction of bleeding phenotype through in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells, which is expected to enhance its recognition in the gene therapy field.
- Clinical Research Presentation: At the American Society of Clinical Oncology Annual Meeting on May 30, INOVIO will present findings on B cell responses in patients with Recurrent Respiratory Papillomatosis treated with its DNA immunotherapy INO-3107, potentially providing new data to support clinical applications of its products.
- Technological Innovation: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases, with its technology optimizing the design and delivery of innovative DNA medicines, which may lead new trends in the biotechnology sector.
- Information Sharing: INOVIO has announced that available abstracts will be shared on its website following the conferences, further enhancing its transparency and influence in the scientific community, which is expected to attract more attention from investors and researchers.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
INOVIO to Release Q1 2026 Financial Results on May 13
- Earnings Release Schedule: INOVIO will announce its Q1 2026 financial results after market close on May 13, providing crucial insights into the company's financial health and operational performance, which will aid investors in assessing market positioning.
- Conference Call Details: Following the earnings release, INOVIO will host a conference call and webcast at 4:30 p.m. ET, where financial results will be discussed and a business update provided, enhancing engagement with investors.
- Webcast Availability: The live webcast will be archived for 90 days, ensuring that investors who cannot attend in real-time can access key information, thereby improving transparency and communication between the company and its stakeholders.
- Company Overview: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and preventing HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
INOVIO to Present at Key Scientific Conferences on DNA Medicines
- Conference Participation: INOVIO will present its research on gene transfer in hemophilia A mice at the American Society of Gene and Cell Therapy Annual Meeting on May 12, 2026, showcasing the correction of bleeding phenotype through in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells, which is expected to enhance its recognition in the gene therapy field.
- Clinical Research Presentation: At the American Society of Clinical Oncology Annual Meeting on May 30, INOVIO will present findings on B cell responses in patients with Recurrent Respiratory Papillomatosis treated with its DNA immunotherapy INO-3107, potentially providing new data to support clinical applications of its products.
- Technological Innovation: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases, with its technology optimizing the design and delivery of innovative DNA medicines, which may lead new trends in the biotechnology sector.
- Information Sharing: INOVIO has announced that available abstracts will be shared on its website following the conferences, further enhancing its transparency and influence in the scientific community, which is expected to attract more attention from investors and researchers.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
INOVIO to Release Q1 2026 Financial Results on May 13
- Earnings Release Schedule: INOVIO will announce its Q1 2026 financial results after market close on May 13, providing crucial insights into the company's financial health and operational performance, which will aid investors in assessing market positioning.
- Conference Call Details: Following the earnings release, INOVIO will host a conference call and webcast at 4:30 p.m. ET, where financial results will be discussed and a business update provided, enhancing engagement with investors.
- Webcast Availability: The live webcast will be archived for 90 days, ensuring that investors who cannot attend in real-time can access key information, thereby improving transparency and communication between the company and its stakeholders.
- Company Overview: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and preventing HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
